POMDOCTOR Plans 1-for-18 Reverse ADS Split to Address Nasdaq Delisting Risk
POM sits 69% above its 52-week low of $0.065 on light trading volume (0.2× avg).
Summary
POMDOCTOR Ltd announced a 1-for-18 reverse ADS split, effective around June 22, 2026, to increase its ADS trading price and address the Nasdaq delisting notice it recently received.
Key Events · Corporate Governance and Compliance · POM
-
Announces 1-for-18 Reverse ADS Split
POMDOCTOR Ltd plans to change its ADS ratio from 1 ADS representing 1/6 Class A ordinary share to 1 ADS representing 3 Class A ordinary shares, effectively a 1-for-18 reverse ADS split for holders.
-
Aims to Address Nasdaq Delisting Notice
This action is intended to increase the ADS trading price, which is crucial for the company to regain compliance with Nasdaq's minimum bid price requirement following a recent delisting notice.
-
Effective Date in June
The ADS Ratio Change is anticipated to be effective on or about June 22, 2026, subject to SEC filing effectiveness.
-
No Impact on Underlying Shares
The change only affects the ADS ratio and will not impact the company's underlying Class A ordinary shares or result in their issuance or cancellation.
Analysis · POM · Trade & Services
This planned 1-for-18 reverse ADS split is a direct response to the Nasdaq delisting notice disclosed in POMDOCTOR's recent 20-F filing. While reverse splits are often viewed negatively, this action is critical for the company to attempt to regain compliance with Nasdaq's minimum bid price requirement and avoid being delisted, which would severely impact its ability to raise capital and investor confidence.
At the time of this filing, POM was trading at $0.11 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $16.1M. The 52-week trading range was $0.06 to $6.43. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.